Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches

Abstract

Tuberculosis (TB) is an infection caused by Mycobacterium tuberculosis (Mtb) and one of the deadliest infectious diseases in the world. Mtb has the ability to become dormant within the host and to develop resistance. Hence, new antitubercular agents are required to overcome problems in the treatment of multi-drug-resistant Tb (MDR-Tb) and extensively drug-resistant Tb (XDR-Tb) along with shortening the treatment time. Several efforts are being made to develop very effective new drugs for Tb, within the pharmaceutical industry, the academia and through public-private partnerships. This review will address the antitubercular activities, biological target, mode of action, synthetic approaches and thoughtful concept for the development of several new drugs currently in the clinical trial pipeline (up to October 2019) for tuberculosis. The aim of this review may be very useful in scheming new chemical entities (NCEs) for Mtb.

Resistant Tuberculosis: A Comprehensive Health Predicament

“…Kumar et al (2021)77 suggested controlling TB by 2030. Health professionals must ensure the following strategies.…”

“…Subsequently, the spread of infection drastically reduced. Furthermore, government agencies and non-government voluntary working groups in the field must exterminate paucity, improve access to healthcare, ensure adequate protection, and strengthen communities to develop robust policies and systems to stop TB77 . Figure1depicts history and principal findings of this paper.…”

Synergistic Li/Li Bimetallic System for the Asymmetric Synthesis of Antituberculosis Drug TBAJ-587

“…Moreover, multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are spreading worldwide, causing major global health issues . Therefore, much effort has been made to develop effective new drugs for the treatment of TB . As a result, the first MDR antituberculosis drug bedaquiline (BDQ), a new ATP synthase inhibitor, was approved by the FDA in 2012 as the first antituberculosis-specific drug .…”

“… 2 Therefore, much effort has been made to develop effective new drugs for the treatment of TB. 3 As a result, the first MDR antituberculosis drug bedaquiline (BDQ), a new ATP synthase inhibitor, was approved by the FDA in 2012 as the first antituberculosis-specific drug. 4 This also paved the way for medicinal chemists to discover new ATP synthase inhibitors that were more effective and potent against MDR/XDR-TB.…”